Latest Ranbaxy Laboratories Stories
PRINCETON, N.J., May 29, 2012 /PRNewswire/ -- Ranbaxy Laboratories Inc. (RLI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), today announced today that the U.S. Food and Drug Administration (FDA) has approved Absorica(TM), a novel, patented brand formulation of the acne medication isotretinoin, for the treatment of severe recalcitrant nodular acne. Through a business agreement with the Canadian firm, Cipher Pharmaceuticals Inc., RLI is expected to launch...
Product to be launched as Absorica(TM) Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, May 27, 2012 /PRNewswire/ - Cipher Pharmaceuticals Inc. (TSX: DND; OTC: CPHMF.PK) announced today that the U.S. Food and Drug Administration (FDA) has approved Absorica(TM), Cipher's novel, patented brand formulation of the acne medication isotretinoin, for the treatment of severe recalcitrant nodular acne. Absorica is expected to be launched in the U.S. in Q4 2012. "Approval of...
Product to be launched as Absorica(TM) Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, May 27, 2012 /PRNewswire/ - Cipher Pharmaceuticals Inc. (TSX: DND; OTC: CPHMF.PK) announced today that the U.S. Food and Drug Administration (FDA) has approved Absorica(TM), Cipher's novel, patented brand formulation of the acne medication isotretinoin, for the treatment of severe recalcitrant nodular acne. Absorica is expected to be launched in the U.S. in Q4 2012. "Approval of...
MIAMI BEACH, Fla., Feb. 9, 2012 /PRNewswire/ -- Today Divine Skin (OTC Bulletin Board: DSKX) released preliminary revenue figures for the fourth quarter, $3.1 million, up 63 percent over the same quarter of 2010 and up 48 percent over the third quarter of 2011. For the year 2011, revenue totaled $9.6 million, up 78 percent over 2010. Divine Skin CEO Daniel Khesin said, "While we experienced nearly triple-digit growth in 2011, we are far from satisfied with this result. We believe...
Generic drug manufacturer agrees to remedy deviations from the current good manufacturing practice requirements and to correct data integrity problems at numerous facilities SILVER SPRING, Md., Jan. 25, 2012 /PRNewswire-USNewswire/ -- The Department of Justice, on behalf of the U.S. Food and Drug Administration, has filed a consent decree of permanent injunction against generic drug manufacturer Ranbaxy in the U.S. District Court of Maryland. The consent decree was filed against...
MIAMI BEACH, Fla., Dec. 21, 2011 /PRNewswire/ -- The team at Divine Skin (OTC Bulletin Board: DSKX) has been working to maintain strong growth and exceed expectations across its diverse consumer goods business and accelerate development through its strong biotechnology program. Some highlights for the year include: RECORD 2010 REVENUE. Divine Skin started the year by announcing record sales for 2010 ($5.4 million), up $1.9 million or 55 percent over 2009. RECORD 2011 QUARTERS....
MIAMI BEACH, Fla., July 18, 2011 /PRNewswire/ -- Biotech pioneer Divine Skin Inc. (DSKX) announced a partnership with India's largest pharmaceutical company, Ranbaxy Laboratories, to sell the DS Laboratories line of topical hair-growth treatments through its massive distribution pipeline. With its strong presence in the top pharmaceutical markets, Ranbaxy offers Divine Skin an expanded global distribution network. With its innovative line of hair-growth products, Divine Skin offers Ranbaxy...
GURGAON, India and PRINCETON, N.J., Nov. 30, 2010 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc., a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced that RLL has received final approval from the U.S. Food and Drug Administration to manufacture and market Donepezil Hydrochloride Tablets 5 mg and 10 mg with 180-day market exclusivity in the U.S. healthcare system. Total annual market sales for Aricept® 5 mg and 10 mg tablets were $2.6 billion (IMS-MAT: September...
JACKSONVILLE, Fla., March 15 /PRNewswire/ -- Ranbaxy Laboratories Limited, along with its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc. (collectively, "Ranbaxy"), announced today that they have reached an agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Ranbaxy's generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15 mg, 30 mg and 45 mg tablets. Under terms of the...
MISSISSAUGA, ON, Nov. 11 /PRNewswire-FirstCall/ - Nuvo Research Inc. (TSX: NRI), a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced a new licensing agreement for Oxoferin(TM), its topical wound healing agent, and additional details of the funding assistance to be...
